IL239495B - Antibody purification by cation exchange chromatography - Google Patents

Antibody purification by cation exchange chromatography

Info

Publication number
IL239495B
IL239495B IL239495A IL23949515A IL239495B IL 239495 B IL239495 B IL 239495B IL 239495 A IL239495 A IL 239495A IL 23949515 A IL23949515 A IL 23949515A IL 239495 B IL239495 B IL 239495B
Authority
IL
Israel
Prior art keywords
cation exchange
exchange chromatography
antibody purification
antibody
purification
Prior art date
Application number
IL239495A
Other languages
Hebrew (he)
Other versions
IL239495A0 (en
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40262967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL239495(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL239495A0 publication Critical patent/IL239495A0/en
Publication of IL239495B publication Critical patent/IL239495B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
IL239495A 2007-10-30 2015-06-18 Antibody purification by cation exchange chromatography IL239495B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98382507P 2007-10-30 2007-10-30
PCT/US2008/081516 WO2009058812A1 (en) 2007-10-30 2008-10-29 Antibody purification by cation exchange chromatography

Publications (2)

Publication Number Publication Date
IL239495A0 IL239495A0 (en) 2015-08-31
IL239495B true IL239495B (en) 2019-09-26

Family

ID=40262967

Family Applications (4)

Application Number Title Priority Date Filing Date
IL205310A IL205310A0 (en) 2007-10-30 2010-04-25 Antibody purification by cation exchange chromatography
IL234901A IL234901A0 (en) 2007-10-30 2014-09-30 Antibody purification by cation exchange chromatography
IL234902A IL234902A0 (en) 2007-10-30 2014-09-30 Antibody purification by cation exchange chromatography
IL239495A IL239495B (en) 2007-10-30 2015-06-18 Antibody purification by cation exchange chromatography

Family Applications Before (3)

Application Number Title Priority Date Filing Date
IL205310A IL205310A0 (en) 2007-10-30 2010-04-25 Antibody purification by cation exchange chromatography
IL234901A IL234901A0 (en) 2007-10-30 2014-09-30 Antibody purification by cation exchange chromatography
IL234902A IL234902A0 (en) 2007-10-30 2014-09-30 Antibody purification by cation exchange chromatography

Country Status (32)

Country Link
US (3) US20090148435A1 (en)
EP (4) EP2840090B1 (en)
JP (5) JP5237382B2 (en)
KR (3) KR20150008503A (en)
CN (3) CN101889025B (en)
AR (2) AR069097A1 (en)
AU (1) AU2008318865B2 (en)
BR (1) BRPI0817182A2 (en)
CA (1) CA2703279C (en)
CL (1) CL2008003218A1 (en)
CO (1) CO6280422A2 (en)
CY (1) CY1116129T1 (en)
DK (3) DK2565206T3 (en)
ES (3) ES2533266T5 (en)
HK (4) HK1143821A1 (en)
HR (2) HRP20150282T4 (en)
HU (3) HUE037409T2 (en)
IL (4) IL205310A0 (en)
ME (1) ME02101B (en)
MX (1) MX2010004740A (en)
NZ (1) NZ584839A (en)
PE (1) PE20091434A1 (en)
PH (1) PH12013501128A1 (en)
PL (3) PL2215117T5 (en)
PT (1) PT2215117E (en)
RS (1) RS53850B2 (en)
RU (1) RU2498991C2 (en)
SG (2) SG10201401690XA (en)
SI (3) SI2840090T1 (en)
TW (2) TWI448330B (en)
WO (1) WO2009058812A1 (en)
ZA (2) ZA201002850B (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044859A2 (en) 2003-11-05 2005-05-19 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
TWI441646B (en) * 2005-01-21 2014-06-21 Genentech Inc Use of pertuzumab in the manufacture of a medicament for treating cancer in a human patient
ES2440481T3 (en) 2005-02-23 2014-01-29 Genentech, Inc. Time extension until disease progression or survival in ovarian cancer patients using pertuzumab
BRPI0716762A2 (en) 2006-09-13 2013-09-24 Abbott Lab cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
RU2498991C2 (en) * 2007-10-30 2013-11-20 Дженентек, Инк. Purification of antibodies with cation-exchange chromatography
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
AR073295A1 (en) 2008-09-16 2010-10-28 Genentech Inc METHODS TO TREAT PROGRESSIVE MULTIPLE SCLEROSIS. MANUFACTURING ARTICLE.
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CA2738499A1 (en) 2008-10-20 2010-04-29 Abbott Laboratories Viral inactivation during purification of antibodies
EP2921501A1 (en) 2008-10-20 2015-09-23 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
WO2011037983A1 (en) * 2009-09-23 2011-03-31 Medarex, Inc. Cation exchange chromatography
CA2787952C (en) * 2010-02-23 2016-07-26 Genentech, Inc. Anti-angiogenesis therapy for the treatment of ovarian cancer
TWI426920B (en) * 2010-03-26 2014-02-21 Hoffmann La Roche Bispecific, bivalent anti-vegf/anti-ang-2 antibodies
PE20130192A1 (en) * 2010-03-30 2013-02-27 Centocor Ortho Biotech Inc IL-25 HUMANIZED ANTIBODIES
ES2788198T3 (en) 2010-05-14 2020-10-20 Univ Oregon Health & Science Recombinant hCMV and hCMV vectors encoding a heterologous antigen isolated from hepatitis B virus and uses thereof
SI2575847T2 (en) * 2010-05-25 2022-08-31 F. Hoffmann-La Roche Ag Methods of purifying polypeptides
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
WO2012084829A1 (en) * 2010-12-21 2012-06-28 F. Hoffmann-La Roche Ag Isoform enriched antibody preparation and method for obtaining it
CN107915769A (en) 2011-03-29 2018-04-17 葛兰素史密斯克莱有限责任公司 Buffer solution system for protein purification
EP2714713B1 (en) * 2011-05-26 2018-05-09 Dr. Reddy's Laboratories Limited Purification of anti-cd20 antibodies
LT2691530T (en) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2013054250A1 (en) * 2011-10-10 2013-04-18 Dr Reddy's Laboratories Limited Purification method
CN104334189A (en) 2011-10-14 2015-02-04 霍夫曼-拉罗奇有限公司 Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
RU2478646C1 (en) * 2011-11-28 2013-04-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им.В.А.Энгельгардта Российской академии наук (ИМБ РАН) Method for producing high-affinity polyclonal antibodies
TR201815709T4 (en) 2011-12-22 2018-11-21 Hoffmann La Roche Ion exchange membrane chromatography.
HRP20211641T1 (en) 2012-07-13 2022-02-04 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
JP6253584B2 (en) * 2012-08-27 2017-12-27 旭化成メディカル株式会社 Antibody purification method by temperature-responsive chromatography
CN103217499B (en) * 2013-01-15 2015-12-02 珠海市丽珠单抗生物技术有限公司 A kind ofly measure the glycosylation of immunoglobulin charge isomer and the method for end modified situation
RU2768003C2 (en) * 2013-03-08 2022-03-22 Джензим Корпорейшн Integrated continuous production of therapeutic protein-based medicinal agents
UY35517A (en) * 2013-04-04 2014-10-31 Mabxience S A A PROCEDURE TO INCREASE THE FORMATION OF PYROGLUTAMIC ACID OF A PROTEIN
NZ751877A (en) 2013-04-16 2020-04-24 Genentech Inc Pertuzumab variants and evaluation thereof
KR101700580B1 (en) 2013-10-30 2017-02-13 (주)셀트리온 Method for separating antibody isoform by using cation exchange chromatography
CN104628846B (en) * 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 Method for purifying recombinant protein
MX2016006551A (en) 2013-11-25 2016-09-06 Seattle Genetics Inc Preparing antibodies from cho cell cultures for conjugation.
TWI709569B (en) 2014-01-17 2020-11-11 美商健臻公司 Sterile chromatography resin and use thereof in manufacturing processes
TWI709570B (en) 2014-01-17 2020-11-11 美商健臻公司 Sterile chromatography and manufacturing processes
KR102382402B1 (en) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
KR101921552B1 (en) 2014-03-10 2018-11-23 리히터 게데온 닐트. Immunoglobulin purification using pre-cleaning steps
CN105017418B (en) * 2014-03-27 2021-02-23 上海药明康德新药开发有限公司 Monoclonal antibody purification process
WO2015164665A1 (en) 2014-04-25 2015-10-29 Genentech, Inc. Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
AU2015289560B2 (en) 2014-07-16 2018-09-27 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
CN105315369B (en) * 2014-07-25 2020-03-13 山东博安生物技术有限公司 Purification of proteins by cation exchange chromatography
EP3268100A1 (en) * 2015-03-13 2018-01-17 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
CN107614015A (en) 2015-05-30 2018-01-19 豪夫迈·罗氏有限公司 Treat HER2 positives Locally Advanced or the previously method of untreated metastatic breast cancer
KR101657690B1 (en) * 2015-06-05 2016-09-19 주식회사 녹십자홀딩스 Methods for Preparing Hepatitis B immune globulin derived from plasma
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN116926128A (en) 2015-11-20 2023-10-24 俄勒冈健康与科学大学 CMV vectors comprising microRNA recognition elements
GB201600512D0 (en) 2016-01-12 2016-02-24 Univ York Recombinant protein production
SG11201808426XA (en) 2016-04-15 2018-10-30 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
EP3454903A4 (en) * 2016-05-13 2020-08-19 Askgene Pharma, Inc. Novel angiopoietin 2, vegf dual antagonists
ES2841648T3 (en) * 2016-07-15 2021-07-08 Hoffmann La Roche Procedure to purify PEGylated erythropoietin
CN106222222B (en) * 2016-08-08 2019-10-29 湖北医药学院 A kind of preparation method of recombinant human leukemia inhibitory
WO2018045587A1 (en) * 2016-09-12 2018-03-15 广东东阳光药业有限公司 Purification method for anti-vegf type monoclonal antibody
CN106380519B (en) * 2016-10-17 2019-11-01 深圳万乐药业有限公司 A kind of purification process of monoclonal antibody
BR112019007982A2 (en) 2016-10-18 2019-07-02 Univ Oregon Health & Science cytomegalovirus vectors eliciting t cells restricted by histocompatibility complex molecules and major
WO2018078158A1 (en) * 2016-10-31 2018-05-03 Hexal Ag Antibody preparation
TW201827077A (en) 2016-12-28 2018-08-01 美商建南德克公司 Treatment of advanced her2 expressing cancer
SI3570884T1 (en) 2017-01-17 2021-02-26 Genentech, Inc. Subcutaneous her2 antibody formulations
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
BE1025090B1 (en) * 2017-03-30 2018-10-29 Univercells Sa PROCESS AND KIT FOR PROTEIN PURIFICATION
KR102140693B1 (en) * 2017-04-14 2020-08-05 에이치케이이노엔 주식회사 Method of Purifying Analogous Antibody Using Cation Exchange Chromatography
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain
MX2019015304A (en) 2017-06-21 2020-02-17 Cephalon Inc Cation exchange chromatography wash buffer.
JP2020534332A (en) * 2017-09-22 2020-11-26 イミュノジェン， インコーポレイテッド Separation of triple light chain antibody using cation exchange chromatography
CN110272491B (en) * 2018-03-13 2023-01-24 江苏恒瑞医药股份有限公司 Purification process of anti-PD-1 antibody
CN112313248A (en) * 2018-03-29 2021-02-02 百时美施贵宝公司 Method for purifying monomeric monoclonal antibodies
US11612885B2 (en) * 2018-05-08 2023-03-28 Waters Technologies Corporation Methods, compositions and kits useful for pH gradient cation exchange chromatography
JP2021536353A (en) 2018-08-31 2021-12-27 ジェンザイム・コーポレーション Aseptic chromatographic resin and its use in manufacturing methods
EP3643322A1 (en) * 2018-10-26 2020-04-29 Mabion SA Low aggregate anti cd20 ligand formulation
CN109320611B (en) * 2018-10-31 2022-06-03 鼎康(武汉)生物医药有限公司 Purification method of human-mouse chimeric monoclonal antibody biological similar drug
CN112206327A (en) * 2019-07-12 2021-01-12 上海药明生物技术有限公司 Preparation of antibody coupling drug and high-throughput screening method thereof
WO2021076489A1 (en) * 2019-10-14 2021-04-22 Pierce Biotechnology, Inc. Peptide purification formulations and methods
BR112022010069A2 (en) * 2019-11-25 2022-09-06 Akeso Biopharma Inc BIESPECIFIC ANTIBODY, ISOLATED NUCLEIC ACID MOLECULE, VECTOR, HOST CELL, CONJUGATE, KIT, USE OF BIESPECIFIC ANTIBODY AND PHARMACEUTICAL COMPOSITION
KR102153258B1 (en) * 2020-02-21 2020-09-07 프레스티지바이오로직스 주식회사 Optimized Method for Purification of Bevacizumab
US11416468B2 (en) * 2020-07-21 2022-08-16 International Business Machines Corporation Active-active system index management
CN114591438B (en) * 2022-04-25 2023-12-05 达石药业(广东)有限公司 Method for purifying bispecific antibody by cation exchange chromatography
WO2024090489A1 (en) * 2022-10-26 2024-05-02 日本メジフィジックス株式会社 Method for producing radioactive pharmaceutical composition
CN115850493B (en) * 2022-11-08 2024-03-12 江苏耀海生物制药有限公司 Separation and purification method of bivalent nano antibody cablevi
CN117756878A (en) * 2023-12-26 2024-03-26 康日百奥生物科技(苏州)有限公司 Antibody chromatographic separation method and application

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
GB2070818A (en) 1980-02-04 1981-09-09 Philips Electronic Associated Regulated power supply for an image intensifier
WO1984002129A1 (en) 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Human immune interferon protein and process for its preparation
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5169774A (en) * 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
WO1986002068A1 (en) 1984-09-26 1986-04-10 Takeda Chemical Industries, Ltd. Mutual separation of proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5196323A (en) 1985-04-27 1993-03-23 Boehringer Ingelheim International Gmbh Process for preparing and purifying alpha-interferon
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
CA1283072C (en) 1986-12-01 1991-04-16 Timothy Durance Process for the isolation and separation of lysozyme and avidin from eggwhite
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5451662A (en) 1987-10-23 1995-09-19 Schering Corporation Method of purifying protein
US5118796A (en) 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
IT1219874B (en) 1988-03-18 1990-05-24 Fidia Farmaceutici USE OF THE HUMAN NERVE GROWTH FACTOR AND ITS PHARMACEUTICAL COMPOSITIONS
US5115101A (en) 1988-06-08 1992-05-19 Miles Inc. Removal of protein A from antibody preparations
WO1989012463A1 (en) 1988-06-21 1989-12-28 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5112951A (en) 1989-07-28 1992-05-12 Hybritech Incorporated Separation of anti-metal chelate antibodies
US5110913A (en) 1990-05-25 1992-05-05 Miles Inc. Antibody purification method
EP0467466A1 (en) * 1990-07-16 1992-01-22 Eastman Kodak Company Method for the purification of immunoreactive labeled thyroxine conjugates
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
EP0602126B1 (en) 1991-08-14 2003-03-05 Genentech, Inc. Immunoglobulin variants for specific fc epsilon receptors
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
DK1136556T3 (en) 1991-11-25 2005-10-03 Enzon Inc Process for the preparation of multivalent antigen-binding proteins
JPH05202098A (en) 1992-01-29 1993-08-10 Snow Brand Milk Prod Co Ltd Production of physiologically active substance from lactic material
CA2129663C (en) 1992-02-06 2005-07-05 James S. Huston Biosynthetic binding protein for cancer marker
US5279823A (en) 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
WO1994004188A1 (en) 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5714338A (en) 1993-12-10 1998-02-03 Genentech, Inc. Methods for diagnosis of allergy
MX9602818A (en) 1994-01-18 1997-06-28 Genentech Inc A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS.
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc Antibody and antibody fragments for inhibiting the growth of tumors
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ES2183131T3 (en) 1996-01-23 2003-03-16 Genentech Inc ANTI-CD18 ANTIBODIES USED AGAINST CEREBRAL ICTUS.
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
NZ335207A (en) 1996-11-15 2000-09-29 Genentech Inc Process to isolate recombinant human neurotrophin using hydrophobic chromatography resin
DE69739673D1 (en) * 1996-11-27 2009-12-31 Genentech Inc Affinity Purification of Polypeptide Proteins on a Protein A Matrix
CA2272842C (en) 1996-11-27 2012-05-15 Genentech, Inc. Humanized anti-cd11a antibodies
DE69842174D1 (en) 1997-04-07 2011-04-21 Genentech Inc Method of producing humanized antibodies by randomized mutagenesis
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2273415T3 (en) 1997-04-07 2007-05-01 Genentech, Inc. ANTI-VEGF ANTIBODIES.
JP2001511653A (en) 1997-05-15 2001-08-14 ジェネンテク，インコーポレイテッド Apo-2 receptor
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
SI1308455T1 (en) * 1998-05-06 2006-08-31 Genentech Inc A composition comprising anti-HER2 antibodies
DE69919701T2 (en) 1998-06-01 2005-09-15 Genentech, Inc., South San Francisco SEPARATION OF ANTIBODY MONOMERS FROM THEIR MULTIMERS BY ION EXCHANGE CHROMATOGRAPHY
KR100501263B1 (en) 1998-06-09 2005-07-18 스태튼스 세룸 인스티튜트 Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
SI1189641T1 (en) 1999-06-25 2009-12-31 Genentech Inc HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
DE60039448D1 (en) 1999-10-29 2008-08-21 Genentech Inc AGAINST PROSTATE-STATE-TEMPORARY (PSCA) ANTIBODIES AND THEIR USE
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
US6417355B1 (en) 2001-04-11 2002-07-09 The United States Of America As Represented By The Secretary Of The Navy Geminal-dinitro-1-5 diazocine derivatives
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US6770027B2 (en) * 2001-10-05 2004-08-03 Scimed Life Systems, Inc. Robotic endoscope with wireless interface
US7151164B2 (en) 2002-02-14 2006-12-19 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
CA2476675A1 (en) 2001-10-17 2003-04-24 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2004001007A2 (en) * 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
SI1543038T2 (en) * 2002-09-11 2020-12-31 Genentech, Inc. Protein purification
EP3284753B1 (en) 2002-10-17 2019-06-05 Genmab A/S Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis
EP1569690B1 (en) 2002-12-13 2011-07-27 Mitra Medical Technology AB Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
NZ571243A (en) 2002-12-31 2010-04-30 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers comprising human growth hormone and protamine
EP1614693A4 (en) * 2003-03-31 2006-07-19 Kirin Brewery Purification of human monoclonal antibody and human polyclonal antibody
JP5416338B2 (en) 2003-05-09 2014-02-12 デューク ユニバーシティ CD20-specific antibody and method of use thereof
AR044388A1 (en) 2003-05-20 2005-09-07 Applied Molecular Evolution CD20 UNION MOLECULES
AU2004263538B2 (en) 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
KR100524074B1 (en) 2003-10-01 2005-10-26 삼성전자주식회사 Electronic device having bezel structure
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
CN101022829A (en) * 2004-04-16 2007-08-22 健泰科生物技术公司 Treatment of polychondritis or mononeuritis multiplex by using an antibody against CD20
AR049021A1 (en) * 2004-04-16 2006-06-21 Genentech Inc TREATMENT OF DISORDERS WITH AN ANTIBODY THAT JOINS CD20
WO2006069403A2 (en) * 2004-12-22 2006-06-29 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
KR101660575B1 (en) * 2005-03-11 2016-09-27 와이어쓰 엘엘씨 A method of weak partitioning chromatography
ES2402650T3 (en) * 2005-06-17 2013-05-07 Janssen Alzheimer Immunotherapy Anti A beta antibody purification methods
WO2007028154A2 (en) * 2005-09-02 2007-03-08 Northwestern University Encapsulated arsenic drugs
CA2645739A1 (en) * 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
CA2911000A1 (en) * 2006-04-05 2007-10-18 Min W. Wan Antibody purification
FI2061803T4 (en) * 2006-08-28 2023-03-14 Process for the purification of fc-containing proteins
US8620738B2 (en) 2006-08-31 2013-12-31 Visa U.S.A. Inc Loyalty program incentive determination
EP2077859A4 (en) * 2007-03-30 2010-11-24 Medimmune Llc Antibody formulation
RU2498991C2 (en) * 2007-10-30 2013-11-20 Дженентек, Инк. Purification of antibodies with cation-exchange chromatography
US9813410B2 (en) 2014-06-26 2017-11-07 Rakuten, Inc. Information processing apparatus, information processing method, and information processing program

Also Published As

Publication number Publication date
HK1182401A1 (en) 2013-11-29
RS53850B2 (en) 2018-07-31
JP2013173747A (en) 2013-09-05
KR20140015166A (en) 2014-02-06
JP2015155406A (en) 2015-08-27
ME02101B (en) 2015-10-20
EP2215117B1 (en) 2014-12-31
ES2533266T5 (en) 2018-04-18
WO2009058812A1 (en) 2009-05-07
PH12013501128A1 (en) 2015-12-02
IL239495A0 (en) 2015-08-31
AU2008318865B2 (en) 2012-06-28
HUE027668T2 (en) 2016-11-28
JP2011502161A (en) 2011-01-20
RU2010121816A (en) 2011-12-10
PL2215117T3 (en) 2015-06-30
IL234902A0 (en) 2014-11-30
SI2565206T1 (en) 2016-07-29
AR111171A2 (en) 2019-06-12
EP2840090A1 (en) 2015-02-25
CN101889025B (en) 2013-11-13
US20180118781A1 (en) 2018-05-03
SG10201401690XA (en) 2014-06-27
RU2498991C2 (en) 2013-11-20
SI2840090T1 (en) 2018-05-31
EP2215117A1 (en) 2010-08-11
HUE037409T2 (en) 2018-08-28
NZ584839A (en) 2012-07-27
AU2008318865A1 (en) 2009-05-07
US9896478B2 (en) 2018-02-20
CN105315323A (en) 2016-02-10
JP5237382B2 (en) 2013-07-17
CL2008003218A1 (en) 2009-03-06
HRP20150282T4 (en) 2018-08-10
CO6280422A2 (en) 2011-05-20
IL205310A0 (en) 2010-12-30
ZA201002850B (en) 2011-07-27
PE20091434A1 (en) 2009-10-17
KR20100086015A (en) 2010-07-29
TWI448330B (en) 2014-08-11
CA2703279C (en) 2014-04-22
EP2565206A3 (en) 2013-11-06
DK2565206T3 (en) 2016-06-06
HK1221234A1 (en) 2017-05-26
HRP20180943T1 (en) 2018-08-10
EP2840090B1 (en) 2018-02-21
TW200927289A (en) 2009-07-01
JP2017019790A (en) 2017-01-26
ES2533266T3 (en) 2015-04-08
ZA201102169B (en) 2012-12-27
PL2840090T3 (en) 2018-07-31
CN103554215B (en) 2016-06-15
CN103554215A (en) 2014-02-05
JP2015145371A (en) 2015-08-13
EP2565206A2 (en) 2013-03-06
DK2840090T3 (en) 2018-04-23
EP2215117B2 (en) 2018-01-10
HK1206753A1 (en) 2016-01-15
IL234901A0 (en) 2014-11-30
KR101241486B1 (en) 2013-03-15
US20090148435A1 (en) 2009-06-11
HK1143821A1 (en) 2011-01-14
TWI554517B (en) 2016-10-21
DK2215117T3 (en) 2015-03-02
SG175597A1 (en) 2011-11-28
AR069097A1 (en) 2009-12-30
ES2666170T3 (en) 2018-05-03
JP5885864B2 (en) 2016-03-16
US20150056196A1 (en) 2015-02-26
CA2703279A1 (en) 2009-05-07
SI2215117T1 (en) 2015-03-31
CN101889025A (en) 2010-11-17
CY1116129T1 (en) 2017-02-08
PT2215117E (en) 2015-04-01
HRP20150282T1 (en) 2015-06-19
MX2010004740A (en) 2010-05-27
PL2215117T5 (en) 2018-06-29
ES2572958T3 (en) 2016-06-03
HUE024877T2 (en) 2016-02-29
PL2565206T3 (en) 2017-08-31
EP2565206B1 (en) 2016-03-30
DK2215117T4 (en) 2018-04-09
SI2215117T2 (en) 2018-04-30
KR20150008503A (en) 2015-01-22
TW201512216A (en) 2015-04-01
BRPI0817182A2 (en) 2015-03-17
EP3441402A1 (en) 2019-02-13
RS53850B1 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
HK1221234A1 (en) Antibody purification by cation exchange chromatography
IL194236A0 (en) Antibody purification
IL201388A0 (en) Immunoglobulin purification
HK1138790A1 (en) Anti-sclerostin antibodies
PT2195026E (en) Anti-sclerostin antibodies
EP2265129A4 (en) Chromatography purification of antibodies
EP2519536A4 (en) Protein purification by ion exchange
PL1985871T3 (en) System for attaching two parts to one another
IL225720A0 (en) Single unit ion exchange chromatography antibody purification
EP2125890A4 (en) Antibodies to phosphorylated-irak4
IL212646A0 (en) Immunoglobulin purification
EP2212431A4 (en) Antibodies to irem-1
HK1198653A1 (en) Protein purification by anion exchange chromatography
HK1198588A1 (en) Protein purification by anion exchange chromatography
ZA201100565B (en) Antibody purification
IL211067A0 (en) Affinity purification by cohesin-dockerin interaction
GB0517651D0 (en) Alterations to pipe movement apparatus
GB0724148D0 (en) Improvements relating to column chromatography

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees